Subgroup analysis suggested that patients with large, localized tumors benefited from the addition of etoposide, whereas patients with metastases did not. There was no difference in EFS between ...
Round dose to nearest 50mg increment. Range: 70mg/m 2 per day for 4 days to 100mg/m 2 per day for 5 days. Repeat course every 3 to 4 weeks after recovery (esp myelosuppression). Renal impairment ...
Suggested remit: To appraise the clinical and cost effectiveness of serplulimab with carboplatin and etoposide within its marketing authorisation for untreated extensive-stage small-cell lung cancer.